CONDENSED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended
	Mar. 31, 2012	Mar. 31, 2011
Revenue:
Genetic testing	$ 677,168	$ 719,447
Other	716	38
Total revenue	677,884	719,485
Cost of revenue	376,211	357,589
Gross profit	301,673	361,896
Operating expenses:
Research and development	446,274	304,820
Selling, general and administrative	1,136,649	1,202,454
Amortization of intangibles	28,863	28,863
Total operating expenses	1,611,786	1,536,137
Loss from operations	(1,310,113)	(1,174,241)
Other income (expense):
Interest income	743	2,406
Interest expense	(105,336)	(88,151)
Gain on disposal of assets		4,275
Total other expense	(104,593)	(81,470)
Loss before income taxes	(1,414,706)	(1,255,711)
Benefit for income taxes
Net loss	$ (1,414,706)	$ (1,255,711)
Basic and diluted net loss per common share	$ (0.04)	$ (0.03)
Weighted average common shares outstanding, basic and diluted	36,748,063	36,618,010